Viking Therapeutics VKTX is preparing to release its quarterly earnings on Wednesday, 2024-10-23. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Viking Therapeutics to report an earnings per share (EPS) of $-0.25.
Anticipation surrounds Viking Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Earnings Track Record
Last quarter the company beat EPS by $0.07, which was followed by a 28.31% increase in the share price the next day.
Here's a look at Viking Therapeutics's past performance and the resulting price change:
Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
---|---|---|---|---|
EPS Estimate | -0.27 | -0.28 | -0.26 | -0.22 |
EPS Actual | -0.20 | -0.26 | -0.25 | -0.23 |
Price Change % | 28.000000000000004% | 6.0% | 18.0% | -9.0% |
Market Performance of Viking Therapeutics's Stock
Shares of Viking Therapeutics were trading at $64.34 as of October 21. Over the last 52-week period, shares are up 484.35%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
To track all earnings releases for Viking Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.